• Japanese
  • Korean
  • Chinese
Cover Image

Generic and Innovative Drugs Market in Central Europe 2013: Comparative Analysis, Reimbursement Policies and Development Forecasts for 2013-2015

  • Published:
  • 302 Pages
  • PMR

This publication explores the markets for generic and innovative medicines in Poland, Romania, Slovakia, the Czech Republic, Hungary and Bulgaria.

In addition to data describing the value of these segments in each country, it offers complete discussion of issues that currently affect the market and will influence future expansion, such as: reimbursement procedures, rules governing pricing, expiry of drug patents and data exclusivity.

This report supplies corporate profiles of drug manufacturers and explains how each of these six Central European countries deals with counterfeit medicines. Detailed forecasts for the period 2013-2015 include estimates of the effects of upcoming legislative changes on these market segments.

Explore this comprehensive collection of market topics:

  • Values of the generic and innovative drug segments in Central European markets for the period 2009-2014
  • Market size of generics in each of the six CE countries/forecasts to 2015
  • Market size of innovative drugs and treatments in each of the six CE countries/ forecasts to 2015
  • Share of the overall pharmaceutical market occupied by generic and innovative drugs for each country included in the report
  • Reimbursement systems and processes in place in each of the six countries
  • Reimbursement lists - latest modifications and upcoming changes
  • Price regulations for reimbursed and non-reimbursed medications
  • Medication mark-ups - official rates and averages
  • Attitudes of consumers and the medical community toward generic and innovative drugs and therapies
  • Forecast changes for the markets in each of the six CE countries
  • Forecast changes in medical reimbursement policies in the six CE countries
  • Latest modifications to drug reimbursement lists; plus forecasts
  • Most influential generic and innovative drug manufacturers in Central Europe and in each specific country covered by the report
  • Supplementary Protection Certificates (SPCs), expiration dates of drug patents and data exclusivity in each country
  • Market share represented by counterfeit products and regulatory environments in each country regarding these products
  • Sales statistics and top selling preparations.
  • VAT rates on drugs.

Consult this report for answers to your questions about the CE generic and innovative drug market:

  • What value has been placed on the Central European generic and innovative drug market during the years 2009-2014?
  • According to forecasts, which country's generic drug market will experience the quickest growth between 2013-2015?
  • According to forecasts, which country's innovative drug market will experience the quickest growth between 2013-2015?
  • What do patients and physicians think about the use of generic and innovative medicines and therapies in Central European countries?
  • In what ways are drug prices regulated in Central European countries with regard to reimbursement status?
  • What are the reimbursement procedures in each of the countries covered by this report? How are they expected to change in the years ahead and what impact will these changes have on the industry?
  • Which recent regulatory actions have most affected the generic and innovative drug markets in Central Europe?
  • What patent expiry periods apply in each of the countries featured in this report?
  • What data exclusivity periods apply in each of the highlighted countries?
  • Which generic and innovative drugs posted the highest sales in Central Europe?
  • Which companies produce the highest value of generic and innovative drugs in each of the featured Central European countries: Poland, Romania, Slovakia, the Czech Republic, Hungary and Bulgaria?

This report is a significant market information source because:

  • It describes the generic and innovative drug markets in Poland, Czech Republic, Slovakia, Romania, Hungary and Bulgaria statistically and through comparative analysis
  • It supplies precise, accurate forecasts for these markets to 2015.
  • It contains detailed facts and analysis on complex topics such as pricing and reimbursement processes and procedures in each country
  • It gathers all information relevant to the industry for all six CE countries and presents it in a single publication at a user-friendly price.

This publication is specially prepared for industry decision makers that represent:

  • Companies engaged in the production and distribution of generic and innovative drug preparations in the Central European region
  • New and potential entrants to one or more of the countries comprising the Central European pharmaceutical market
  • Companies that provide business consulting, analysis and research services
  • Government agencies, academic and research institutes
  • Financial services providers in banking, brokerage, private equity and other investment options
  • Pharmaceutical industry trade groups, commerce organisations.

The professionals listed above will consult this document whenever they:

  • Consider, plan or execute plans for market entry involving generic and innovative drugs in Central Europe
  • Creating or adjusting a product portfolio for this market
  • Assess regulatory policy in any of the Central European countries featured in this report
  • Question the potential for growth in the generic and innovative drug markets in the countries of Central Europe or the overall regional market
  • Survey the latest changes to regional reimbursement lists
  • Create forecasts for performance and growth within the Central European generic drug segment overall or in one or more of the countries featured in this report
  • Create forecasts for performance and growth within the Central European innovative drug segment overall or in one or more of the countries featured in this report.

Table of Contents

  • I. Methodology
  • II. Executive summary
  • III. Characteristics of generic and innovative drug markets in Central European countries
  • IV. Bestselling drugs in Central Europe
  • V. Counterfeit products
  • VI. Reimbursement and pricing policies in Central Europe
  • VII. Key manufacturers
  • VIII. List of graphs
  • IX. List of tables
  • X. About PMR
Show More
Pricing
Get Notified
Email me when related reports are published